Thursday, February 12, 2009

Microdosing could be a win/win for pharma, CROs

According to Peter Mansell of Pharma Times, a new study by Frost & Sullivan, Strategic Analysis of Opportunities in the CRO Market – Phase 0, notes the increasing acceptance of microdosing and suggests it may be the antidote to industry’s much-discussed problems with drug productivity. Consolidation among CROs has raised concerns about quality of service and attention to detail in the sector, Frost & Sullivan points out. Mansell points out that companies need to ensure these elements are in place if they are to maintain their bargaining power with the pharmaceutical industry. For more information on the study or Peter Mansell's thoughts, check out the original article, here.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment